A Phase 2a Multiple Dose Basket Design” Study Of The Safety, Tolerability, And Pharmacologic Activity Of BT200 In Patients With Hereditary Bleeding Disorders - BT200-02

Start Date16 Dec 2020

Sponsor / Collaborator

Medical University of Vienna

NCT04677803 / CompletedPhase 2IIT

A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders

BT200 is a PEGylated aptamer that binds to the A1 domain of human von Willebrand factor (VWF). At low doses, BT200 blocks the clearance of VWF antigen (VWF Ag) from the circulation and causes an increase in concentrations of both VWF Ag and Factor VIII (FVIII), but has negligible effect on the activity of either. At higher doses, BT200 blocks clearance of VWF and also inhibits its activity, but still does not inhibit FVIII activity. Therefore, low dose BT200 could potentially be used to correct deficiency of VWF and/or FVIII in patients with hereditary bleeding disorders. This study is designed as a "basket design" pilot study to determine the relevant dose and pharmacological activity of BT200 in such patients.
In this open basket study up to 25 patients with the following congenital blood-clotting disorders are to be included: Patients with hemophilia A, heterozygous carriers of hemophilia A with subnormal FVIII levels; patients with von Willebrand syndrome (VWD) type 1, "Vicenza type", and with VWD type 2b.
Participants will receive BT200 subcutaneously on day 0, day 4 and day 7 in the first week and then once a week for a total of five weeks - initially in a dose of 3 mg, then in week 3 individually after response in a dose of 3 to 9 mg.
Subsequently, blood samples are taken once a week for a further three weeks (wash-out phase).
Patients may be enrolled in an additional pharmacokinetics sub-study. For this purpose, approximately three blood samples are taken to estimate the half-life of substituted FVIII under the influence of BT200.
The primary objective of this study is to obtain clinical proof of mechanism for BT200 in one or more hereditary bleeding disorders.

Start Date14 Dec 2020

Sponsor / Collaborator

Medical University of Vienna

100 Clinical Results associated with Rondaptivon Pegol

100 Translational Medicine associated with Rondaptivon Pegol

100 Patents (Medical) associated with Rondaptivon Pegol

Literatures (Medical) associated with Rondaptivon Pegol

01 Oct 2024·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Aptamer BT200 is protective against myocardial ischemia-reperfusion injury in mice

Article

Author: Wang, Ruowen ; Yuan, Ancai ; Xie, Yuquan ; Chen, Xinyuan ; Lu, Guiping ; Ma, Yue ; Pu, Jun ; Liao, Xianying

BACKGROUND:

Myocardial ischemia-reperfusion (MI/R) injury tends to affect cardiac function and leads to poor patient prognosis, and there is still no effectively targeted drug to develop anti-von Willebrand factor (VWF) aptamer in acute coronary heart disease. However, the newly anti-VWF aptamer BT200 is applied not only for stroke and hemophilia but also for antithrombolism function in clinical development. The role of BT200 in acute myocardial injury during MI/R is still unknown.

OBJECTIVES:

To investigate the cardioprotective effect of aptamer BT200 in a mouse model of MI/R.

METHODS:

C57BL/6 mice were subjected to 30-minute ischemia and 24-hour reperfusion to establish MI/R model. Mice were treated with intravenous injection of cy3-labeled BT200 and were observed by an in vivo imaging system at different time points. Then, mice were sampled and evaluated by echocardiography, Evans triphenyltetrazolium chloride staining, histopathologic, western blotting, and real-time quantitative polymerase chain reaction assays to detect cardiac injury and inflammation response after 24-hour reperfusion.

RESULTS:

BT200 aptamer can enter and infiltrate into the ischemic myocardium after 24-hour reperfusion. BT200 was shown to inhibit VWF A1 activity and prolong bleeding time in MI/R mice. Moreover, BT200-treated mice had a significant reduction in infarct size and an improvement in cardiac function post-MI/R. BT200 treatment can also alleviate MI/R-induced microvascular obstruction, inflammation response, and cardiomyocyte apoptosis.

CONCLUSION:

Pharmacologic targeting of VWF with BT200 alleviates acute MI/R injury in a murine model and may be a novel therapy strategy for acute myocardial infarction.

26 Sep 2024·BLOOD

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1

Article

Author: Jilma, Bernd ; Baker, Ross I. ; Byrne, Ciara ; Chion, Alain ; McKinnon, Thomas A. J. ; O’Donnell, James S. ; Fazavana, Judicael ; Gilbert, James C. ; Preston, Roger J. S. ; Karampini, Ellie ; Aguila, Sonia ; Doherty, Dearbhla ; Zhu, Shuhao ; Atiq, Ferdows ; Amin, Aamir ; Emsley, Jonas ; Lopes, Patricia

Abstract:

Rondaptivon pegol (previously BT200) is a pegylated RNA aptamer that binds to the A1 domain of von Willebrand factor (VWF). Recent clinical trials demonstrated that BT200 significantly increased plasma VWF–factor VIII levels by attenuating VWF clearance. The biological mechanism(s) through which BT200 attenuates in vivo clearance of VWF has not been defined. We hypothesized that BT200 interaction with the VWF-A1 domain may increase plasma VWF levels by attenuating macrophage-mediated clearance. We observed that full-length and VWF-A1A2A3 binding to macrophages and VWF-A1 domain binding to lipoprotein receptor–related protein 1 (LRP1) cluster II and cluster IV were concentration-dependently inhibited by BT200. Additionally, full-length VWF binding to LRP1 expressed on HEK293T (HEK-LRP1) cells was also inhibited by BT200. Importantly, BT200 interacts with the VWF-A1 domain in proximity to a conserved cluster of 4 lysine residues (K1405, K1406, K1407, and K1408). Alanine mutagenesis of this K1405-K1408 cluster (VWF-4A) significantly (P < .001) attenuated binding of VWF to both LRP1 clusters II and IV. Furthermore, in vivo clearance of VWF-4A was significantly (P < .001) reduced than that of wild-type VWF. BT200 did not significantly inhibit binding of VWF-4A to LRP1 cluster IV or HEK-LRP1 cells. Finally, BT200 interaction with the VWF-A1 domain also inhibited binding to macrophage galactose lectin and the SR-AI scavenger receptor. Collectively, our findings demonstrate that BT200 prolongs VWF half-life by attenuating macrophage-mediated clearance and specifically the interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1. These data support the concept that targeted inhibition of VWF clearance pathways represents a novel therapeutic approach for von Willebrand disease and hemophilia A.

26 Dec 2023·Blood advances

New and emerging therapies for women, girls, and people with the potential to menstruate with VWD

Article

Author: James, Paula D ; Casari, Caterina ; Leung, Jennifer

Abstract:

Innovation in therapies for patients with von Willebrand disease (VWD) has lagged far behind that for hemophilia, creating inequity in the bleeding disorder community. Although currently existing treatments of antifibrinolytics, desmopressin, and plasma-derived von Willebrand factor replacement are considered effective, multiple studies report poor quality of life in patients with VWD, especially those with heavy menstrual bleeding (HMB). This disconnect underscores the need for novel therapies that are safe and effective and that consider a patient’s specific contraceptive and reproductive needs. Recombinant von Willebrand factor is the most recent new therapy for VWD; the data specific to women are reviewed. We also present emerging data on emicizumab for the treatment of VWD, BT200 (rondoraptivon pegol), generalized hemostatic therapies (VGA039 and HMB-011), as well as treatments based on nanotechnology (platelet-inspired nanoparticles and KB-V13A12). We are optimistic as we move toward pivotal clinical trials for these elegant and innovative treatments.

News (Medical) associated with Rondaptivon Pegol

03 Aug 2023

·www.globenewswire.com

Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform

Intellectual property relates to key features of the company’s liquid jet injection technologySAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,707,610 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract,” and has allowed U.S. Application No. 16/839,107 entitled, “Ingestible Device for Delivery of a Dispensable Substance.” Both are directed to ingestible devices for delivery of a dispensable substance to the gastrointestinal tract of a subject. “These latest patents cover key features of our unique liquid jet injection technology, including its energy source, thereby broadening the scope of protection around our BioJet platform,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We believe we hold one of the most robust ingestible device patent portfolios, and these recent additions further strengthen our position and highlight the innovative approach we are taking to achieve category-leading bioavailability of large molecules using an oral pill,” continued Mr. Mohanty. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 11 issued patents and 27 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. These patents are part of Biora’s larger corporate portfolio consisting of 73 patent families, including approximately 180 issued patents and 145 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico. About the BioJet™ Systemic Oral Delivery Platform Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases. The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the intestinal tissue for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation up to 400µL. Biora is developing multiple molecules for delivery via the BioJet platform, including BT-002, a drug-device combination consisting of a variant of adalimumab delivered via the BioJet device for the treatment of inflammatory conditions, and BT-200, which consists of a GLP-1 receptor agonist delivered via the BioJet device for the treatment of type 2 diabetes. The company is currently advancing preclinical development of both programs. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 38 issued patents and pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. About Biora TherapeuticsBiora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter. Safe Harbor Statement or Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor ContactChuck PadalaManaging Director, LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390 Media Contactmedia@bioratherapeutics.com

03 Aug 2023

·www.biospace.com

Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery PlatformIntellectual property relates to key features of the company’s liquid jet injection technology

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,707,610 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract,” and has allowed U.S. Application No. 16/839,107 entitled, “Ingestible Device for Delivery of a Dispensable Substance.” Both are directed to ingestible devices for delivery of a dispensable substance to the gastrointestinal tract of a subject. “These latest patents cover key features of our unique liquid jet injection technology, including its energy source, thereby broadening the scope of protection around our BioJet platform,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We believe we hold one of the most robust ingestible device patent portfolios, and these recent additions further strengthen our position and highlight the innovative approach we are taking to achieve category-leading bioavailability of large molecules using an oral pill,” continued Mr. Mohanty. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 11 issued patents and 27 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. These patents are part of Biora’s larger corporate portfolio consisting of 73 patent families, including approximately 180 issued patents and 145 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico. About the BioJet™ Systemic Oral Delivery Platform Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases. The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the intestinal tissue for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation up to 400µL. Biora is developing multiple molecules for delivery via the BioJet platform, including BT-002, a drug-device combination consisting of a variant of adalimumab delivered via the BioJet device for the treatment of inflammatory conditions, and BT-200, which consists of a GLP-1 receptor agonist delivered via the BioJet device for the treatment of type 2 diabetes. The company is currently advancing preclinical development of both programs. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 38 issued patents and pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. About Biora Therapeutics Biora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter. Safe Harbor Statement or Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we the SEC. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor Contact Chuck Padala Managing Director, LifeSci Advisors IR@bioratherapeutics.com (646) 627-8390 Media Contact media@bioratherapeutics.com

08 Jun 2023

·www.biospace.com

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany. Details of the presentations are as follows: Abstract Title: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery Platform in Swine Presentation No: 635 Discussion Session: SO 44 Novel Incretins Date: Tuesday, October 3, 2023, 13:45 to 14:45 CEST Presenting Author: Shaoying Nikki Lee, PhD, Director, Clinical and Translational Science, Biora Therapeutics, Inc. Abstracts will be published on the EASD website on July 1, 2023. Short oral presentations are embargoed until 12:30 CEST on October 3, 2023. Details of the presentation will also be made available on the Biora Therapeutics website following the meeting. About the BioJet™ Systemic Oral Delivery Platform Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases. The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the intestinal tissue for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation up to 400µL. Biora is developing multiple molecules for delivery via the BioJet platform, including BT-002, a drug-device combination consisting of a variant of adalimumab delivered via the BioJet device for the treatment of inflammatory conditions, and BT-200, which consists of a GLP-1 receptor agonist delivered via the BioJet device for the treatment of type 2 diabetes. The company is currently advancing preclinical development of both programs. About Biora Therapeutics Biora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter. Safe Harbor Statement or Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we the SEC. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Investor Contact Chuck Padala Managing Director, LifeSci Advisors IR@bioratherapeutics.com (646) 627-8390 Media Contact media@bioratherapeutics.com

100 Deals associated with Rondaptivon Pegol

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemophilia A	Phase 3	US	Band Therapeutics LLC	30 Jan 2022
Von Willebrand Disease, Type 2	Phase 3	US	Band Therapeutics LLC	30 Jan 2022
Von Willebrand Disease, Type 1	Phase 2	US	Band Therapeutics LLC	30 Jan 2022
Von Willebrand Disease, Type 3	Phase 2	US	Band Therapeutics LLC	30 Jan 2022
Atherosclerosis	Phase 1	AT	Band Therapeutics LLC	07 Oct 2019
Intracranial Arteriosclerosis	Phase 1	AT	Band Therapeutics LLC	07 Oct 2019
Stroke	Phase 1	AT	Band Therapeutics LLC	07 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISTH2021	Phase 2	Hemophilia A	-	BT200	vlaczyybsz(qpstzvfgvt) = alsjunebwv bmdqheygle (gsgwyyxklv, 129 - 421) View more	-	17 Jul 2021
ISTH2021	Phase 2	Von Willebrand Disease, Type 2	5	BT200	gbftnzwzwk(apgyspovmj) = elyuxgxoeu mjfngcuifp (hhnxdzwvsm ) View more	-	17 Jul 2021
ISTH2019	Not Applicable	-	-	Desmopressin	yjuuqnnvnc(akcmjhlibs) = vrjflgwgjh wdkdwtjozm (sawjkyjtwf )	-	10 Jun 2019
ISTH2019	Not Applicable	-	-	Endotoxin	yjuuqnnvnc(akcmjhlibs) = vfahnupxvv wdkdwtjozm (sawjkyjtwf )	-	10 Jun 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rondaptivon Pegol

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation